| CAS: | 2304-80-5 | ||
| 分子式: | C36H73NO3 | ||
| 分子量: | 567.96976 | ||
| 英文名称: |
| ||
| 用途: | C18 dihydro Ceramide is a bioactive sphingolipid and precursor in the de novo synthesis of C18 ceramide that lacks the 4,5-trans double bond. |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | 详情 | ||||||||||||||||||||
| C911246 | MACKLIN | C18 dihydro Ceramide (d18:0/18:0) | 98% | 370元/1mg; 1441元/5mg; | 展开 | ||||||||||||||||||||
储存：-20°C，密闭，干燥 状态：白色到灰白色固体 | |||||||||||||||||||||||||
| 860627P | Avanti | C18 Dihydroceramide (d18:0/18:0) | Avanti Polar Lipids 860627P, powder | 1033.4元/5 MG; 3995.76元/25 MG; | 展开 | ||||||||||||||||||||
产品说明 一般描述 C18 Dihydroceramide (d18:0/18:0) or N-Stearoylsphinganine is a synthetic lipid. Acylation of sphinganine with stearoyl (FA-CoA with C18 acyl chain) by dihydro ceramide synthase 1, yields C18-dihydroceramide. 应用 C18 Dihydroceramide (d18:0/18:0) has been used as a standard for the quantitation of sphingolipid metabolites in adipose tissues by quadrupole time-of-flight (Q-TOF) mass spectrometry. 生化/生理作用 Dihydroceramides act as precursors for ceramides in the mammalian de-novo sphingolipid pathway. vitamin D supplementation increases plasma C18 dihydroceramide (C18-DHC) levels in type 2 diabetes mellitus (T2D) patients. Low serum concentration of C18-DHC has been observed in patients with history of graft rejection and ischemic type biliary lesions (ITBL). Therefore, it can be used as a predictor of graft rejection. 包装 5 mL Amber Glass Screw Cap Vial (860627P-25mg) 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||
m.cnreagent.com